Related Experiment Video
Updated: Jul 12, 2025

Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases
Published on: August 2, 2022
A Rare Case of Refractory Catastrophic Antiphospholipid Syndrome Successfully Treated With Rituximab and Plasma
Ayrton Bangolo1, Sowmya Sagireddy1, Sarah Mahamadeen1
1Department of Internal Medicine, Hackensack University Medical Center/Palisades Medical Center, North Bergen, NJ, USA.
Abstract:
A small subset of patients with antiphospholipid syndrome (APS) may develop widespread thrombotic disease with organ damage, referred to as catastrophic APS (CAPS) that is associated with a high mortality. Medical therapy typically involves a combination of anticoagulation, systemic glucocorticoids, plasmapheresis, and intravenous immune globulin (IVIG). There is currently no consensus for the management of refractory cases of CAPS. However, monoclonal antibodies such as rituximab and eculizumab have shown some benefits. Herein, we present a 29-year-old female with previous pulmonary embolism who presented with necrotic left toes and was eventually diagnosed with refractory CAPS, successfully treated with Plasmapheresis and Rituximab. With this case report, we hope to encourage the usage of Rituximab in the management of CAPS.
More Related Videos
Related Concept Videos
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Venous Thrombosis III: Interprofessional Care
Rheumatic Heart Disease III: Medical Management
Peripheral Artery Disease III: Interprofessional Care
Continuous Renal Replacement Therapy
Psychosis: Goals of Pharmacotherapy

